Anti-TNF-α therapy, administered alone or in combination with canakinumab (monoclonal antibody anti-IL-1β), was found to be an effective treatment for HS symptoms, further substantiating the role of these cytokines in the disease pathogenesis [71]. This evidence concerns the gene TNF and histiocytic sarcoma.